fda compounding semaglutide crackdown news today 2025 The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the FDA Takes Aim at Hims

The commercial dosing may differ when the drug eventually launches

They can often track your luggage and have it delivered as soon as possible

One of the great things about fillers is that they can benefit you at any point in your weight loss journey

Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1 Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes

Amanda Parker for this article about how semaglutides impact mental health

Many people on lower doses encounter this issue with larger 5 mL vials, and switching to smaller volumes or higher concentrations can help maximize what you use before the expiration window closes